Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study
| Autor: | Philippe Ardisson, Jean-Paul Guastalla, Pierre Meeus, Agathe Bajard, Armelle Dufresne, Isabelle Moullet, Lionel Vincent, Isabelle Ray-Coquard, Intidhar Labidi Galy, Jean-Emmanuel Kurtz, David Coeffic, Irène Asmane, Olivier Tredan, Jean-Pierre Bergerat |
|---|---|
| Přispěvatelé: | Department of Medical Oncology [Lyon], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Informatique de Robotique et de Microélectronique de Montpellier (LIRMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Altération génétique des cancers, chimioprévention et réponse thérapeutique, Département d'Oncologie Médicale, Equipe 14, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Département de Médecine Nucléaire, Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Equipe 11, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC) |
| Rok vydání: | 2011 |
| Předmět: |
Vascular Endothelial Growth Factor A
Oncology Cancer Research MESH: Rectovaginal Fistula MESH: Taxoids Angiogenesis Inhibitors Docetaxel Carcinoma Ovarian Epithelial Gastroenterology Carboplatin MESH: Antibodies Monoclonal chemistry.chemical_compound 0302 clinical medicine MESH: Carboplatin Ovarian carcinoma Antineoplastic Combined Chemotherapy Protocols MESH: Urinary Bladder Fistula Neoplasms Glandular and Epithelial MESH: Angiogenesis Inhibitors MESH: Treatment Outcome Ovarian Neoplasms MESH: Aged 0303 health sciences MESH: Middle Aged Antibodies Monoclonal Vinorelbine Hematology General Medicine Middle Aged 3. Good health Bevacizumab Vascular endothelial growth factor MESH: Ovarian Neoplasms MESH: Antineoplastic Combined Chemotherapy Protocols Treatment Outcome Paclitaxel 030220 oncology & carcinogenesis Female Taxoids medicine.drug Adult medicine.medical_specialty MESH: Neoplasms Glandular and Epithelial MESH: Vinblastine [SDV.CAN]Life Sciences [q-bio]/Cancer MESH: Drug Administration Schedule Antibodies Monoclonal Humanized Vinblastine Drug Administration Schedule MESH: Intestinal Fistula 03 medical and health sciences Internal medicine Intestinal Fistula medicine Carcinoma Humans Radiology Nuclear Medicine and imaging MESH: Paclitaxel Cyclophosphamide Aged Retrospective Studies 030304 developmental biology MESH: Humans Urinary Bladder Fistula business.industry MESH: Vascular Endothelial Growth Factor A Rectovaginal Fistula MESH: Cyclophosphamide MESH: Adult MESH: Retrospective Studies medicine.disease chemistry Intestinal Perforation MESH: Antibodies Monoclonal Humanized MESH: Intestinal Perforation Ovarian cancer business MESH: Female |
| Zdroj: | Bulletin du Cancer Bulletin du Cancer, 2011, 98 (9), pp.80-9. ⟨10.1684/bdc.2011.1436⟩ Bulletin du Cancer, John Libbey Eurotext, 2011, 98 (9), pp.80-9. ⟨10.1684/bdc.2011.1436⟩ |
| ISSN: | 0007-4551 1769-6917 |
| Popis: | International audience; OBJECTIVES. As vascular endothelial growth factor (VEGF) is expressed in ovarian cancer, we assessed the efficacy and safety of bevacizumab (a monoclonal antibody targeting VEGF) plus microtubule targeting agents for heavily pre-treated ovarian carcinoma patients. METHODS. We retrospectively reviewed 43 patients with recurrent epithelial ovarian carcinoma. Combined treatment included bevacizumab with paclitaxel in 32 (74%), docetaxel in 10 (23%), and vinorelbine in one (2.3%) patients, respectively. RESULTS. The median number of combined treatment was six cycles (range 1-29). On RECIST criteria, the objective response rate (ORR) was 40% (16% CR and 24% PR). Clinical benefit (complete response [CR] plus partial response [PR] and stable disease [SD] lasting ≥ 3 months) was 74% (CI95%: 46.7-77%). Median duration of treatment and overall survival were 3.9 months (range 0.2-14.4 months) and 20.1 months (CI95%: 13.8-20.1) respectively. No toxic death was reported. Grade 3-4 toxicity occurred in 30% of patients. Gastrointestinal perforations and fistula occurred in 3 (7%) and 6 (14%) patients, respectively. CONCLUSION. Although being active in terms of ORR, bevacizumab plus microtubule targeting agents - mainly taxanes - leads to a high rate of gastro-intestinal perforations and fistula in heavily pre-treated ovarian carcinoma patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|